Updated Results for Nivolumab in MSI-H Colorectal Cancer

Video

Michael J. Overman, MD, medical oncologist, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses updated results from the CheckMate-142 trial, which investigated nivolumab alone or in combination with ipilimumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer. 

Related Videos
Related Content
Legislative Changes and Their Impact on Community Oncology Care

Legislative Changes and Their Impact on Community Oncology Care

April 24th 2024
Article

In an interview with Targeted Oncology, Ben Jones identified the key challenges community oncologists are facing due to legislative changes in cancer care policy.

Read More

Behind the FDA Approval of Fruquintinib for Previously Treated mCRC

Behind the FDA Approval of Fruquintinib for Previously Treated mCRC

November 15th 2023
Podcast

In season 4, episode 18 of Targeted Talks, Arvind Dasari, MD, MS, dives into the recent approval of fruquintinib for patients with metastatic colorectal cancer.

Listen

FDA Approves 177Lu-Dotatate in Patients 12 and Up for GEP-NETs

FDA Approves 177Lu-Dotatate in Patients 12 and Up for GEP-NETs

April 23rd 2024
Article

Read More

Unpacking the Latest Research in Gastrointestinal Cancers

Unpacking the Latest Research in Gastrointestinal Cancers

February 15th 2023
Podcast

In season 4, episode 1 of Targeted Talks, Benjamin L. Schlechter, MD, discuses new studies in the gastrointestinal cancers space.

Listen

Durvalumab Plus Chemo Continues to Improve Survival in Biliary Tract Cancer

Durvalumab Plus Chemo Continues to Improve Survival in Biliary Tract Cancer

April 16th 2024
Article

Results from a 3-year follow-up of the TOPAZ-1 trial showed that treatment with durvalumab plus chemotherapy in advanced biliary tract cancer continued to improve overall survival vs chemotherapy alone.

Read More

Dato-DXd Outperforms Docetaxel in Nonsquamous Lung Cancer

Dato-DXd Outperforms Docetaxel in Nonsquamous Lung Cancer

April 15th 2024
Article

Aaron Lisberg, MD, discussed the phase 3 TROPION-Lung01 study which evaluated datopotamab deruxtecan for patients with advanced or metastatic non-small cell lung cancer.

Read More